Windtree appoints Leanne Kelly to board; launches strategy to acquire small biotechs with equity

WINDTREE THERAPEUTICS INC /DE/

Leanne Kelly appointed as independent director and Audit Committee chair effective Jan 8, 2025.
CEO states new corporate strategy: use equity to acquire small biotechs with FDA-approved products to become revenue-generating.
Company received Nasdaq deficiency notice Dec 4, 2024 for independent director/audit committee; expects Kelly's appointment to resolve.
Kelly is currently CFO of GRI Bio, with over 20 years of public company experience in life sciences and accounting.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Leanne Kelly

director and chair of the Audit Committee

WINT · WINDTREE THERAPEUTICS INC /DE/

Effective: 2025-01-08
Filed: January 13, 2025, 6:59 PM ET

On January 8, 2025, the Board of Directors (the "Board") of Windtree Therapeutics, Inc. (the "Company") approved an increase in the number of directors on the Board to five and appointed Leanne Kelly as a director and member and chair of the Audit Committee, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Leanne Kelly was appointed as director and chair of the Audit Committee at WINDTREE THERAPEUTICS INC /DE/.

Action: appointed
Role: director and chair of the Audit Committee

Exact text from the filing

On January 8, 2025, the Board of Directors (the "Board") of Windtree Therapeutics, Inc. (the "Company") approved an increase in the number of directors on the Board to five and appointed Leanne Kelly as a director and member and chair of the Audit Committee, effective immediately.

View on SEC.gov

WINDTREE THERAPEUTICS INC /DE/ filing history →

Source: SEC EDGAR

accession 0001437749-25-000930

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.